Omega-3/Omega-6 Fatty Acid Metabolism
Polyunsaturated fatty acid (PUFA) metabolism (omega-6: LA (18:2n-6) → FADS2 (Δ6-desaturase; rate-limiting) → GLA (18:3n-6) → ELOVL5 (elongase 5) → DGLA (20:3n-6) → FADS1 (Δ5-desaturase) → AA (20:4n-6) → COX-1/2 → PGE2/TXA2/LTB4; omega-3: ALA (18:3n-3) → FADS2 → SDA (18:4n-3) → ELOVL5 → ETA (20:4n-3) → FADS1 → EPA (20:5n-3) → ELOVL2/5 → DPA (22:5n-3) → Δ6-desaturation → tetracosapentaenoic acid → β-oxidation → DHA (22:6n-3); competition: omega-3 and omega-6 compete for FADS2/FADS1/ELOVL5; ratio determines eicosanoid profile): PGE2 (AA-COX-2; pro-inflammatory; EP1-4 receptors; fever, pain sensitisation, vasodilation); PGE3 (EPA-COX-2; anti-inflammatory; 100-fold less potent than PGE2 at EP2/4; net anti-inflammatory); PGI3 (EPA → prostacyclin synthase; vasodilatory, anti-platelet; replaces pro-aggregatory TXA2); LTB5 (EPA-5-LOX; 10-100× less potent than LTB4 for neutrophil chemotaxis); SPM (specialised pro-resolving mediators: resolvins (RvE1/E2 from EPA; RvD1-6 from DHA); protectins (PD1/neuroprotectin D1 from DHA); maresins (MaR1/2 from DHA in macrophages)); membrane: DHA → phospholipid (PE/PC) remodelling → lipid raft reorganisation → receptor clustering (TLR4, IL-2R, TCR signal attenuation).
Spirulina Mechanisms in Omega-3/Fatty Acid Metabolism
GLA Provision and FADS2 Bypass
FADS2 (Δ6-desaturase; the rate-limiting enzyme in PUFA elongation; encoded by FADS2; requires cytochrome b5/NADH; activity reduced by: ageing (−30–50% in elderly), trans fats, zinc/Mg deficiency, insulin resistance, chronic inflammation (cytokines → FADS2 suppression); genetic polymorphisms (FADS1/2 rs174537, rs174575: reduced enzyme activity in ∼20% population)) is bypassed by spirulina's direct GLA provision: spirulina GLA (20–30 mg/g dry weight; predominantly in glycolipids; among the richest plant GLA sources; evening primrose oil: ~90 mg/g; borage: ~230 mg/g; spirulina: ~20–30 mg/g): GLA enters the elongation cascade at ELOVL5 → DGLA (the critical branch point: DGLA → COX → PGE1 (anti-inflammatory, vasodilatory, cAMP-elevating; vasculoprotective) or DGLA → FADS1 → AA (rate governed by FADS1 activity); GLA → DGLA preferential routing to PGE1 when FADS1 activity is physiologically constrained; this reduces AA production per GLA molecule). Spirulina SDA (stearidonic acid; 18:4n-3; minor; ~1–3 mg/g): SDA bypasses FADS2 in the omega-3 pathway (SDA is the FADS2 product of ALA; direct provision → ELOVL5 → EPA pathway; more efficient EPA elevation than ALA at equivalent doses).
Prostanoid Class Switching: PGE2 to PGE3
Prostanoid class switching (the shift from pro-inflammatory AA-derived eicosanoids (PGE2, TXA2, LTB4) to anti-inflammatory EPA-derived eicosanoids (PGE3, TXA3, LTB5) and SPM occurs through substrate competition at COX-1/2 and 5-LOX; requires elevated cellular EPA:AA ratio) is promoted by spirulina through: (1) GLA → DGLA → competitive FADS1 sequestration (less AA formed from DGLA; more DGLA → PGE1 via COX); (2) SDA → EPA chain elongation (modest EPA elevation supporting EPA:AA ratio); (3) NF-κB suppression (−30–45%) → COX-2 mRNA reduction (−25–40%) → reduced AA-COX-2 flux → PGE2 −20–30% in inflammatory models (LPS/IL-1β-stimulated macrophages); (4) phycocyanin direct COX-2 active site interaction (competitive AA binding inhibition; IC50 ~15–25 µM phycocyanobilin for COX-2 in cell-free assays); (5) omega-3 index elevation (>2g GLA/day theoretical): net PGE2:PGE3 ratio −20–30%; LTB4:LTB5 ratio −15–25%.
FADS1/ELOVL5 Transcriptional Support
FADS1/FADS2/ELOVL5 transcription (PPARα (RXRα partner; binds PPRE in FADS2 promoter; activated by: FA ligands, fibrates, fasting); PPARγ (adipocyte; FADS1 regulation); SREBP-1c (insulin-driven; lipogenic transcription including FADS2); ChREBP (carbohydrate-driven; ELOVL5 target); NF-Y (CCAAT binding factor in FADS1/2 promoters)) is upregulated by spirulina's PPARα activation: phycocyanin/GLA metabolites → PPARα ligand activation → FADS2 promoter PPRE → FADS2 mRNA +10–20%; ELOVL5 (PPARα-target; elongates C18:4 → C20:4 and C20:4 → C22:4; rate-limiting for EPA → DPA step) +10–15%; FADS1 (Δ5-desaturase; ELOVL5 product → EPA) modest support. Net: entire elongation-desaturation pipeline capacity enhanced → more efficient conversion of dietary PUFA to EPA/DHA when fish oil/ALA substrate is co-provided.
Membrane Phospholipid Remodelling
DHA membrane incorporation (Lands cycle: PLs (phospholipids) undergoes remodelling via PLA2 → lysoPL + FA → LPCAT/LPCAT3 (lysophospholipid acyltransferase 3) re-acylation with EPA/DHA → EPA-PE/DHA-PE at sn-2 position; DHA-enriched membranes: ↓TLR4 dimerisation (lipid raft disruption); ↓TCR/BCR signal amplification; ↑TREK-1 K+ channel (neuronal); ↑synaptogenesis (dendritic spine DHA); ↑anti-apoptotic BCL-2/BCL-XL (→BAX suppression)) requires adequate LPCAT3 substrate: LPCAT3 requires activated FA-CoA (FA + CoA → FA-CoA by ACSL4 (arachidonoyl-CoA synthetase 4; also handles EPA/DHA)). Spirulina GLA/SDA provision increases EPA-CoA availability for LPCAT3 sn-2 remodelling; AMPK activation reduces LPCAT3 competing substrate (reducing de novo palmitate incorporation). Membrane EPA incorporation +5–10% in erythrocyte phospholipids (proxy for tissue PL) after 8–12 weeks 10g/day spirulina supplementation in some models.
Clinical Outcomes in Omega-3 Metabolism
- PGE2 (LPS-stimulated; urine/plasma): −20–30%
- LTB4 (neutrophil; 5-LOX product): −15–25%
- DGLA (plasma; GLA metabolite): +15–30%
- Erythrocyte EPA (membrane; omega-3 index): +5–10%
- PGE1 (anti-inflammatory; DGLA-COX): +10–20%
- AA:EPA ratio (plasma phospholipids): −10–20%
Dosing and Drug Interactions
Inflammatory conditions/metabolic syndrome: 5–10g daily; co-provision with EPA/DHA fish oil (1–2g EPA+DHA) amplifies prostanoid class switching synergistically. NSAIDs (ibuprofen, naproxen): Spirulina COX-2 suppression (NF-κB + direct phycocyanin) is complementary to NSAID COX inhibition; reduced NSAID dose requirement theoretically; monitor bleeding risk. Aspirin: Low-dose aspirin TXA2 suppression + spirulina GLA → DGLA → PGE1 (anti-platelet): complementary anti-thrombotic. Fish oil supplements: Spirulina GLA + fish oil EPA/DHA: complementary; spirulina FADS1/ELOVL5 upregulation may enhance ALA → EPA conversion from fish oil precursors; no pharmacological conflict. Zileuton (5-LOX inhibitor): Spirulina LTB4 reduction (substrate competition + NF-κB) is upstream of zileuton (enzyme inhibition); additive in asthma/inflammation models. Summary: PGE2 −20–30%, LTB4 −15–25%, DGLA +15–30%, AA:EPA −10–20%; dosing 5–10g + EPA/DHA daily. NK concern: low.